Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol and Probucol in PAD with CAD
NCT01142284Phase 2Completed
- Sponsor
- Otsuka Holdings
- Start
- May 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilostazol and probucol in peripheral artery disease (PAD) (4 arms), sponsored by Otsuka Holdings. Primary endpoints: Flow-Mediated Dilation at 12 weeks and Safety Assessment at 12 weeks. Started May 2010; status: completed.
02
Drugs
cilostazolprobucol
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01142284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142284.